C4 Therapeutics, Inc.: JP Morgan initiates coverage with overweight rating; $10 price target
CCCC•JP Morgan initiated coverage of C4 Therapeutics with an overweight rating and a $10 price target.
CCCC•CCCC•CCCC•JP Morgan initiated coverage of C4 Therapeutics with an overweight rating and a $10 price target.
